NCT04707079 is a Phase 2 clinical trial of Duvelisib in Follicular Lymphoma, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Who is sponsoring NCT04707079?

NCT04707079 is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

What drugs are being tested in NCT04707079?

Interventions in NCT04707079: Duvelisib.

What condition does NCT04707079 study?

NCT04707079 studies Follicular Lymphoma.

Is NCT04707079 still recruiting?

NCT04707079 is currently status unknown. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT04707079

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Status unknown Phase 2 Last updated 13 January 2021

What this trial tests

Phase 2 trial testing Duvelisib in Follicular Lymphoma in 24 participants. Status unknown.

Timeline

18 December 2019

Primary endpoint
31 October 2021

31 March 2022

Quick facts

Lead sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	18 December 2019
Primary completion	31 October 2021
Estimated completion	31 March 2022
Sites	1 location across China

Drugs / interventions tested

Duvelisib (DUVELISIB) — full drug profile →

Conditions studied

Follicular Lymphoma — all drugs for Follicular Lymphoma →

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in subjects diagnosed with follicular lymphoma (FL) that is relapsed or refractory to either chemotherapy or radioimmunotherapy (RIT).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer.
Quan Z, Yang Y, Zheng H, Zhan Y, et al · · 2022 · cited 81× · PMID 36313041 · DOI 10.7150/jca.77619
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z, Zhou H, Xu J, Wang J, et al · · 2022 · cited 22× · PMID 36685572 · DOI 10.3389/fimmu.2022.1070660

Verify or expand the search:

Other trials of Duvelisib

Trials testing the same drug.

NCT07293403 — Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas · Phase 2 · not yet recruiting
NCT07001384 — A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (AL · Phase 1 · recruiting
NCT06810778 — Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · Phase 1, PHASE2 · recruiting
NCT05923502 — (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) · not yet recruiting
NCT04639843 — Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma · Phase 1 · withdrawn

Other recruiting trials for Follicular Lymphoma

Currently open trials in the same condition.

NCT07128641 — Odronextamab in Low Tumor Volume Advanced FL · Phase 2 · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT07126678 — Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma · NA · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting

Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04707079 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04707079.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing